Phase 2 Stomach Cancer Trial, Recruiting NCT07537348 Sponsor: Qilu Hospital of Shandong University Condition: Stomach Cancer
Back to Stomach Cancer

Phase 2 Stomach Cancer Trial, Recruiting

NCT07537348
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with advanced stomach cancer that has spread to other parts of the body, confirmed by scans (such as CT or PET-CT), and your doctors have recommended a treatment plan that combines chemotherapy and immunotherapy.
  • You are between 18 and 70 years old (any gender).
  • You are able to eat by mouth or receive liquid food through a tube placed through your nose into your stomach.
  • You are willing to take part in this study and have signed the consent form agreeing to participate.
  • You do not currently have any other type of cancer alongside your stomach cancer.

Who may not be able to join:

  • You have a cognitive condition or mental health disorder that makes it difficult for you to understand the study or agree to take part in an informed way.
  • You have been diagnosed with Type 1 or Type 2 diabetes.
  • You have serious gut or digestive problems, such as severe diarrhoea, persistent vomiting, serious difficulty absorbing nutrients, a bowel blockage, or active bleeding in your digestive system.
  • You have a known allergy or sensitivity to any of the main ingredients in the special nutritional powder being studied (confirm with trial site).
  • You are currently taking other nutritional supplements that could interfere with the study results.
  • You are unable to tolerate the combined chemotherapy and immunotherapy treatment, or you have experienced severe digestive side effects from this type of treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-18560085120

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Qilu Hospital of Shandong University
Registry
ClinicalTrials.gov
Start date
1 January 2026
Est. completion
30 June 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Response Evaluation Criteria in Solid Tumors (RECIST) Grade; 1-year survival rate and overall survival (OS); The tumor regression grade (TRG) system; Grade of CTCAE grading system

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov